 |
|
The Incidence of Recurrent Venous Thromboembolism After Treatment With Vitamin K Antagonists in Relation to Time Since First Event
A Meta-analysis
Carlo J. J. van Dongen, MSc;
Roel Vink, MD;
Barbara A. Hutten, PhD;
Harry R. Büller, MD, PhD;
Martin H. Prins, MD, PhD
Arch Intern Med. 2003;163:1285-1293.
Background After a first episode of venous thromboembolism, patients are treated with vitamin K (phytonadione) antagonists. There are indications that the risk of recurrence after treatment with vitamin K antagonists decreases relative to the time since the first event. The aim of the present meta-analysis is to describe the risk of recurrent venous thromboembolism after treatment with vitamin K antagonist in relation to the time since the index event.
Methods Computerized searches in MEDLINE and EMBASE databases; reference checks of pertinent articles; personal communication with colleagues to find randomized clinical trials and cohort studies in which patients with venous thromboembolism were treated with vitamin K antagonists. Per treatment arm, 2 reviewers independently extracted data on the number of recurrent events and the duration of follow-up per time period of 3 months.
Results A total of 135 potentially eligible studies were identified. Of these, 18 studies could be included, comprising 25 treatment arms that could be analyzed. Treatment arms were divided into 3 groups based on treatment duration (short, medium, and long). For all 3 groups, the monthly incidence immediately after discontinuation of treatment was high and declined rapidly thereafter. The monthly incidence after 9 months seemed independent of the treatment duration.
Conclusions There is a diminishing risk of recurrent venous thromboembolism over time and a stabilization after 9 months independent of the duration of the initial treatment with vitamin K antagonists. These findings have important implications for decision making about the optimal duration of treatment with vitamin K antagonists.
From the Departments of Clinical Epidemiology and Biostatistics (Mr van Dongen and Dr Hutten) and Vascular Medicine (Drs Vink and Büller), Academic Medical Center, Amsterdam; and Department of Clinical Epidemiology, Academic Hospital, Maastricht (Dr Prins), the Netherlands. The authors have no relevant financial interest in this article.
RELATED ARTICLE
Duration of Anticoagulation in Venous Thromboembolism
Thomas M. Hyers
Arch Intern Med. 2003;163(11):1265-1266.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study
Legnani et al.
haematol 2008;93:900-907.
ABSTRACT
| FULL TEXT
The Epidemiology of Venous Thromboembolism in the Community
Heit
Arterioscler. Thromb. Vasc. Bio. 2008;28:370-372.
FULL TEXT
A Prospective Long-term Study of 220 Patients With a Retrievable Vena Cava Filter for Secondary Prevention of Venous Thromboembolism
Mismetti et al.
Chest 2007;131:223-229.
ABSTRACT
| FULL TEXT
Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial
den Heijer et al.
Blood 2007;109:139-144.
ABSTRACT
| FULL TEXT
Duration of Anticoagulation Following Venous Thromboembolism: A Meta-analysis
Ost et al.
JAMA 2005;294:706-715.
ABSTRACT
| FULL TEXT
Recurrent Thromboembolism After Treatment With Vitamin K Antagonists
van Dongen et al.
Arch Intern Med 2003;163:2793-2793.
FULL TEXT
Secondary Prophylaxis with Warfarin for Venous Thromboembolism
Buller and Prins
NEJM 2003;349:702-704.
FULL TEXT
Duration of Anticoagulation in Venous Thromboembolism
Hyers
Arch Intern Med 2003;163:1265-1266.
FULL TEXT
|
